Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jun 18:1215:69-75.
doi: 10.1016/j.brainres.2008.03.063. Epub 2008 Apr 6.

The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms

Carl Potenzieri  1 , Catherine Harding-Rose, Donald A Simone
Affiliations

The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms

Carl Potenzieri et al. Brain Res. .

Abstract

Several lines of evidence suggest that cannabinoids can attenuate various types of pain and hyperalgesia through peripheral mechanisms. The development of rodent cancer pain models has provided the opportunity to investigate novel approaches to treat this common form of pain. In the present study, we examined the ability of peripherally administered cannabinoids to attenuate tumor-evoked mechanical hyperalgesia in a murine model of cancer pain. Unilateral injection of osteolytic fibrosarcoma cells into and around the calcaneus bone resulted in tumor formation and mechanical hyperalgesia in the injected hindpaw. Mechanical hyperalgesia was defined as an increase in the frequency of paw withdrawals to a suprathreshold von Frey filament (3.4 mN) applied to the plantar surface of the hindpaw. WIN 55, 212-2 (1.5 to 10 microg) injected subcutaneously into the tumor-bearing hindpaw produced a dose-dependent decrease in paw withdrawal frequencies to suprathreshold von Frey filament stimulation. Injection of WIN 55,212-2 (10 microg) into the contralateral hindpaw did not decrease paw withdrawal frequencies in the tumor-bearing hindpaw. Injection of the highest antihyperalgesic dose of WIN 55,212-2 (10 microg) did not produce catalepsy as determined by the bar test. Co-administration of WIN 55,212-2 with either cannabinoid 1 (AM251) or cannabinoid 2 (AM630) receptor antagonists attenuated the antihyperalgesic effects of WIN 55, 212-2. In conclusion, peripherally administered WIN 55,212-2 attenuated tumor-evoked mechanical hyperalgesia by activation of both peripheral cannabinoid 1 and cannabinoid 2 receptors. These results suggest that peripherally-administered cannabinoids may be effective in attenuating cancer pain.

PubMed Disclaimer

Figures

Figure 1
Figure 1
WIN 55,212-2 dose-dependently attenuates mechanical hyperalgesia in a murine model of cancer pain. Local injection of 2.5, 5, or 10μg of WIN 55,212-2 into the tumor-bearing hindpaw reduced the mean paw withdrawal frequency evoked by a suprathreshold von Frey monofilament (3.4mN). * indicates a significant difference from vehicle (p<0.05).
Figure 2
Figure 2
Antihyperalgesia produced by intraplantar injection of WIN 55,212-2 occurred through peripheral mechanisms. Administration of WIN 55,212-2 (10μg) into the contralateral hindpaw did not decrease paw withdrawal frequencies in the tumor-bearing paw. This indicates that the antihyperalgesia produced by injection of WIN 55,212-2 into the paw did not occur via systemic uptake of the drug
Figure 3
Figure 3
Attenuation of tumor-evoked mechanical hyperalgesia following intraplantar injection of WIN 55,212-2 is not due to catalepsy. Neither vehicle nor 10μg of WIN 55,212-2 increased the amount of time mice spent on the bar. However, intraplantar injection of the 25μg dose of WIN 55,212-2 produced catalepsy. *indicates a significant difference from vehicle (p<0.05).
Figure 4
Figure 4
CB1 and CB2 receptors contribute to the antihyperalgesia produced by WIN 55,212-2. Co-administration of 1 μg of either the CB1 receptor antagonist, AM251 (A), or the CB2 receptor antagonist, AM630 (B) with 10μg of WIN 55,212-2 attenuated the antihyperalgesia produced by WIN 55,212-2. * indicates a significant difference from vehicle (p<0.05); # indicates a significant difference from WIN 55,212-2 (10μg).
See this image and copyright information in PMC

References

    1. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, Mackie K, Marian C, Batkai S, Parolaro D, Fischer MJ, Reeh P, Kunos G, Kress M, Lutz B, Woolf CJ, Kuner R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nature Neuroscience. 2007;10:870–879. - PMC - PubMed
    1. Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary afferent sensory neurons. Neuroscience. 2000;100:685–688. - PubMed
    1. Amaya F, Shimosato G, Kawasaki Y, Hashimoto S, Tanaka Y, Ji RR, Tanaka M. Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist. Pain. 2006;124:175–183. - PubMed
    1. Azevedo São Leão Ferreira K, Kimura M, Jacobsen Teixeira M. The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it? Supportive Care in Cancer. 2006;14:1086–1093. - PubMed
    1. Baamonde A, Lastra A, Juárez L, García V, Hidalgo A, Menéndez L. Effects of the local administration of selective mu-, delta-and kappa-opioid receptor agonists on osteosarcoma-induced hyperalgesia. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2005;372:213–219. - PubMed

Publication types

MeSH terms

Substances